Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)

By sjmartinez • August 9, 2024

Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST, Kuzel TM, Bazzi LA, Daignault-Newton S, Whang YE, Dreicer R, Stephenson RD, Rettig MB, Shevrin D, Gerke T, Chinnaiyan AM, Antonarakis ES. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Aug 8. doi: 10.1158/1078-0432.CCR-24-1402. Epub ahead of print. PMID: 39115414.

Tags: Hematology/Oncology, Publications, Veterans Administration

Related Posts

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer

Zhang S, Queen KJ, Duggirala N, Yang E, Lipsyc-Sharf M, Racz J, Bennett J, Hong K, Suresh Y, Hamilton C, Pitta M, Chien N, La[...]

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchan J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]